Outlook Therapeutics, Inc. Common Stock
$0.65
-$0.03 (-4.17%)
$0.65Day Range$0.70
Key Statistics
Market Cap
$158.87M
Shares Outstanding
243.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 13, 2016
Round Lot
100
Locale
US
Trading Data
Day Open
$0.70
Day High
$0.70
Day Low
$0.65
Volume
5.62M
VWAP
$0.66
Prev Close
$0.68
Transactions
--
Acc. Volume
--
About Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283617 employees111 S. WOOD AVENUE, ISELIN, NJ, 08830(609) 619-3990IPO May 13, 2016US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001649989
- Composite FIGI
- BBG00469JRJ5
- Share Class FIGI
- BBG00469JRM1
- Ticker Root
- OTLK
- SIC Code
- 2836
About Outlook Therapeutics, Inc. Common Stock (OTLK) Stock
Outlook Therapeutics, Inc. Common Stock (OTLK) closed the 2026-09-18 session at $0.65, down 4.17% versus the previous close (-0.03). The stock opened at $0.70 and traded between $0.65 and $0.70 during that session. Session trading volume was 5.6M shares. The volume-weighted average price (VWAP) is $0.66.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Outlook Therapeutics, Inc. Common Stock has a market capitalization of $158.9 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. OTLK is listed on the XNAS exchange. The company employs approximately 17 people. Outlook Therapeutics, Inc. Common Stock is headquartered in ISELIN, NJ. The recorded listing date is 2016-05-13.
On this page you can find market OTLK stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.